Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection

Ming Sound Tsao, Sophie Marguet, Gwénaël Le Teuff, Sylvie Lantuejoul, Frances A. Shepherd, Lesley Seymour, Robert Kratzke, Stephen L. Graziano, Helmut H. Popper, Rafael Rosell, Jean Yves Douillard, Thierry Le-Chevalier, Jean Pierre Pignon, Jean Charles Soria, Elisabeth M. Brambilla

Research output: Contribution to journalArticlepeer-review

225 Scopus citations


Purpose: The classification for invasive lung adenocarcinoma by the International Association for the Study of Lung Cancer, American Thoracic Society, European Respiratory Society, and WHO is based on the predominant histologic pattern-lepidic (LEP), papillary (PAP), acinar (ACN), micropapillary (MIP), or solid (SOL)-present in the tumor. This classification has not been tested in multi-institutional cohorts or clinical trials or tested for its predictive value regarding survival from adjuvant chemotherapy (ACT) Patients and Methods: Of 1,766 patients in the IALT, JBR.10, CALGB 9633 (Alliance), and ANITA ACT trials included in the LACE-Bio study, 725 had adenocarcinoma. Histologies were reclassified according to the new classification and then collapsed into three groups (LEP, ACN/PAP, and MIP/SOL). Primary end point was overall survival (OS); secondary end points were disease-free survival (DFS) and specific DFS (SDFS). Hazard ratios (HRs) and 95% CIs were estimated through multivariable Cox models stratified by trial. Prognostic value was estimated in the observation arm and predictive value by a treatment effect interaction with histologic subgroups. Significance level was set at .01 for pooled analysis. Results: A total of 575 patients were included in this analysis. OS was not prognostically different between histologic subgroups, but univariable DFS and SDFS were worse for MIP/SOL compared with LEP or ACN/PAP subgroup (P < .01); this remained marginally significant after adjustment. MIP/SOL patients (but not ACN/PAP) derived DFS and SDFS but not OS benefit from ACT (OS: HR, 0.71; 95% CI, 0.51 to 0.99; interaction P = .18; DFS: HR, 0.60; 95% CI, 0.44 to 0.82; interaction P = < 01; and SDFS: HR, 0.59; 95% CI, 0.42 to 0.81; interaction P = .01) Conclusion: The new lung adenocarcinoma classification based on predominant histologic pattern was not predictive for ACT benefit for OS, but it seems predictive for disease-specific outcomes.

Original languageEnglish (US)
Pages (from-to)3439-3446
Number of pages8
JournalJournal of Clinical Oncology
Issue number30
StatePublished - Oct 20 2015

Bibliographical note

Publisher Copyright:
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.


Dive into the research topics of 'Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection'. Together they form a unique fingerprint.

Cite this